CNBCLean R·
AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push
AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion, in more than five years.
Read at CNBC →
AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion, in more than five years.
<iframe src="https://statesidedaily.com/embed/cluster/3f8c938de16cf04230c4cc477848a0c496fa40f8" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push"></iframe>